2.30 – 3.15 p.m.
**Trimodal therapy for muscle-invasive cancer: is it really equal?**
Chairs: Eckart Breinl and Harun Fajkovic

Perioperative outcomes from a prospective Austrian radical cystectomy cohort
Stefan Madersbacher, Vienna

**Trimodal therapy is an effective alternative**
Gregor Goldner, Vienna

**Trimodal therapy is too risky**
Richard Zigeuner, Graz

3.15 – 3.45 p.m.
**Coffee break**

3.45 – 4.30 p.m.
**Pathology – the key to risk stratification**
Chairs: Steffen Krause and Lukas Kenner

**News from the WHO**
Eva Comperat, Paris

**Impact of variant histology on outcomes**
Martin Susani, Vienna

**Cytology and other urinary markers: an update**
Helene Wiener, Vienna

4.30 – 5.15 p.m.
**Therapy of metastatic disease**
Chairs: Claus Riedl and Manuela Schmidinger

**Oligometastatic cancer: medical, surgical or combination?**
Paolo Gontero, Turin

**Chemotherapy: state of the art**
Öner Sanlı, Istanbul

**Immunotherapy: revolution or hype?**
Wolfgang Loidl, Linz

5.15 – 6.00 p.m.
**The future**
Chairs: Michael Marberger and Shahrokh F. Shariat

**Clinical trials: what is hot**
Gero Kramer, Vienna

**Urothelial carcinoma in 10 years from now**
Arnulf Stenzl, Tuebingen

**Thank you and Farewell**
Shahrokh F. Shariat, Vienna

---

January 29th 2016
9.00 a.m. - 6.00 p.m.

**Inaugural International Urothelial Carcinoma Meeting**

**Contemporary Concepts and Controversies**

Leading experts will come together to discuss the latest in diagnosis, treatment, and ongoing research in urothelial carcinoma. The conference will contain state-of-the-art lectures, interactive discussions, and unique “point-counterpoint” debates.

[www.meduniwien.ac.at/urology](http://www.meduniwien.ac.at/urology)
Program

9.00 - 9.15 a.m.
Welcome
Michaela Fritz, Vice rector of the Medical University of Vienna

Key concerns about the current state of bladder cancer
Shahrokh F. Shariat, Vienna

9.15 – 10.00 a.m.
Innovations in endoscopic management of non-muscle invasive cancer
Chairs: Michael Marberger and Shahrokh F. Shariat
Hexvix®
Peter Nyriady, Budapest
Hypericin®
Jörg Schmidbauer, Vienna
Narrow band imaging®
Bernard Malavaud, Toulouse
En bloc resection
Tobias Klatte, Vienna

10.00 – 11.15 a.m.
Failing BCG – a major clinical dilemma!
Chairs: Walter Albrecht and Christian Seitz
Are all BCG strains equal?
Alex Bachmann, Basel
How to determine „BCG Failure”
Max Burger, Regensburg
When to choose early radical cystectomy?
Georg Bartsch, Frankfurt
Salvage chemotherapy and Synergo®
Fred Witjes, Nijmegen
Immunocothel®: a novel option?
Volkmar Tauber, Linz

11.15 – 11.45 a.m.
Coffee break

11.45 a.m. – 12.45 p.m.
Radical cystectomy – which technique is best?
Chairs: Christoph Klinger and Franz Stoiber
Open radical cystectomy
Marko Babjuk, Prague
Extraperitoneal radical cystectomy
Karl-Dietrich Sievert, Salzburg
3D laparoscopic radical cystectomy
Piotr Chiosta, Krakow
Robotic radical cystectomy
Christian Schwentner, Stuttgart

12.45 – 1.30 p.m.
Lunch break

1.30 – 2.30 p.m.
Imaging, perioperative chemotherapy, and rehabilitation
Chairs: Michael Rauchenwald and Anton Ponholzer
Imaging for bladder cancer: where are we in 2016?
Pascal Baltzer, Vienna
Perioperative chemotherapy: who, when, and which?
Jakub Dobruch, Warsaw
Enhanced recovery after radical cystectomy: what can we improve?
Yannick Cerantola, Lausanne
Urological rehabilitations following radical surgery: a must
Michael Zellner, Bad Griesbach

This event will be approved by the Austrian Medical Chamber with DFP-points. Free participation.
Program

9.00 - 9.15 a.m.
Welcome
Michaela Fritz, Vice rector of the Medical University of Vienna

Key concerns about the current state of bladder cancer
Shahrokh F. Shariat, Vienna

9.15 – 10.00 a.m.
Innovations in endoscopic management of non-muscle invasive cancer
Chairs: Michael Marberger and Shahrokh F. Shariat
Hexvix®
Peter Nyriady, Budapest
Hypericin®
Jörg Schmidbauer, Vienna
Narrow band imaging®
Bernard Malavaud, Toulouse
En bloc resection
Tobias Klatte, Vienna

10.00 – 11.15 a.m.
Failing BCG – a major clinical dilemma!
Chairs: Walter Albrecht and Christian Seitz
Are all BCG strains equal?
Alex Bachmann, Basel
How to determine „BCG Failure“
Max Burger, Regensburg
When to choose early radical cystectomy?
Georg Bartsch, Frankfurt
Salvage chemotherapy and Synergo®
Fred Witjes, Nijmegen
Immunocothel®: a novel option?
Volkmar Tauber, Linz

11.15 – 11.45 a.m.
Coffee break

11.45 a.m. – 12.45 p.m.
Radical cystectomy – which technique is best?
Chairs: Christoph Klingler and Franz Stoiber
Open radical cystectomy
Marko Babjuk, Prague
Extraperitoneal radical cystectomy
Karl-Dietrich Sievert, Salzburg
3D laparoscopic radical cystectomy
Piotr Chlosta, Krakow
Robotic radical cystectomy
Christian Schwentner, Stuttgart

12.45 – 1.30 p.m.
Lunch break

1.30 – 2.30 p.m.
Imaging, perioperative chemotherapy, and re-habilitation
Chairs: Michael Rauchenwald and Anton Ponholzer
Imaging for bladder cancer: where are we in 2016?
Pascal Baltzer, Vienna
Perioperative chemotherapy: who, when, and which?
Jakub Dobruch, Warsaw
Enhanced recovery after radical cystectomy: what can we improve?
Yannick Cerantola, Lausanne
Urological rehabilitations following radical surgery: a must
Michael Zellner, Bad Griesbach
2.30 – 3.15 p.m.  
**Trimodal therapy for muscle-invasive cancer: is it really equal?**  
**Chairs:** Eckart Breinl and Harun Fajkovic

Perioperative outcomes from a prospective Austrian radical cystectomy cohort  
Stefan Madersbacher, Vienna

Trimodal therapy is an effective alternative  
Gregor Goldner, Vienna

Trimodal therapy is too risky  
Richard Zigeuner, Graz

3.15 – 3.45 p.m.  
**Coffee break**

3.45 – 4.30 p.m.  
**Pathology – the key to risk stratification**  
**Chairs:** Steffen Krause and Lukas Kenner

News from the WHO  
Eva Comperat, Paris

Impact of variant histology on outcomes  
Martin Susani, Vienna

Cytology and other urinary markers: an update  
Helene Wiener, Vienna

4.30 – 5.15 p.m.  
**Therapy of metastatic disease**  
**Chairs:** Claus Riedl and Manuela Schmidinger

Oligometastatic cancer: medical, surgical or combination?  
Paolo Gontero, Turin

Chemotherapy: state of the art  
Öner Sanli, Istanbul

Immunotherapy: revolution or hype?  
Wolfgang Loidl, Linz

5.15 – 6.00 p.m.  
**The future**  
**Chairs:** Michael Marberger and Shahrokh F. Shariat

Clinical trials: what is hot  
Gero Kramer, Vienna

Urothelial carcinoma in 10 years from now  
Arnulf Stenzl, Tuebingen

Thank you and Farewell  
Shahrokh F. Shariat, Vienna

Inaugural International Urothelial Carcinoma Meeting

Contemporary Concepts and Controversies

Leading experts will come together to discuss the latest in diagnosis, treatment, and ongoing research in urothelial carcinoma. The conference will contain state-of-the-art lectures, interactive discussions, and unique “point-counterpoint” debates.

Contact  
Phone: +43 (0)1 40400 – 26150  
Email: shahrokh.shariat@meduniwien.ac.at  
www.bladdercancervienna2016.com

Department of Urology